Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304811 | 0.92 | CYP1A2 (0.35) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6980139 | 0.85 | KDM4E (0.41) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6958872 | 0.80 | KDM4E (0.43) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6979441 | 0.79 | KDM4E (0.41) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL14878205 | 0.78 | KDM4E (0.37) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6959092 | 0.77 | KDM4E (0.46) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6978880 | 0.75 | KDM4E (0.34) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6976911 | 0.72 | OPRL1 (0.33) | CYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL6979961 | 0.71 | KDM4E (0.41) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6978849 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854789-B1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | CYP1A2 1375/4885CYP2D6 1566/4885CYP2C19 554/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | CYP1A2 1375/4885CYP2D6 1566/4885CYP2C19 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.